[Myopathies under therapy with lipid-lowering agents].
Myopathies ranging from myalgia to clinically asymptomatic creatine kinase (CK) elevation and to life-threatening rhabdomyolysis belong to the most important complications of lipid-lowering therapies with fibrates and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, i.e., statins. Rhabdomyolysis is a rare side effect of statin therapy with an estimated incidence of 0.2/1 million prescriptions. Myalgia and muscle cramps were reported by up to 5% of patients, but they were observed with the same percentage in controls receiving placebo. Due to increasing numbers of patients under lipid-lowering therapy, however, more and more patients present in neuromuscular units with the differential diagnosis of a fibrate- or statin-induced myopathy.
Köller
H
H
Neurologische Klinik der Heinrich-Heine-Universität, 40001 Düsseldorf. koellerh@uni-duesseldorf.de
Neuhaus
O
O
Schroeter
M
M
Hartung
H-P
HP
D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D002995:Clofibric Acid / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D009135:Muscular Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011379:Prognosis; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000517:prevention & control*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002995:Clofibric Acid